Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  MediWound Ltd.    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

MOVES-Moelis adds tech banker to expand in Israel - memo

10/21/2020 | 05:00pm EST

Oct 21 (Reuters) - Moelis & Co has hired technology investor Elan Zivotofsky as a managing director to provide financing and transaction advice to Israeli-based companies, the investment bank told staff on Wednesday in an internal memo seen by Reuters.

A spokeswoman for the bank confirmed the contents of the memo.

Zivotofsky formerly led growth-stage venture investments at Ibex Investors, a U.S.-based investment fund focused on Israeli companies. He will be based in Tel Aviv with the aim of helping Moelis expand its business in the Middle Eastern tech hub.

Zivotofsky has spent over 20 years working with Israeli companies as an investment banker and investor. He had led M&A transactions for Checkpoint Software and NICE Systems when he led tech M&A in the region at Lehman Brothers. Later, he invested in companies, including electric bicycle service JUMP Bikes and Wave Financial, according to his LinkedIn page.

Israel, known as a "startup nation," is home to over 6,000 active startups. In the third quarter, Israeli private high-tech companies raised a record $2.74 billion, a 24% year-over-year increase despite the coronavirus pandemic, according to the Israel Venture Capital Research Center and ZAG law firm.

Headquartered in New York, Moelis entered the Middle East market in 2011. Last year, it advised Israeli burn treatment company MediWound in its license agreement with Vericel . The boutique bank is also known for serving as financial adviser to Saudi oil giant Aramco on its record $29.4 billion initial public offering in 2019. (Reporting by Krystal Hu in New York; editing by Jonathan Oatis)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
IBEX 35 -0.24% 8200.7 Delayed Quote.-13.91%
LONDON BRENT OIL 1.77% 48.79 Delayed Quote.-28.42%
MEDIWOUND LTD. 0.27% 3.68 Delayed Quote.18.39%
MOELIS & COMPANY 2.13% 41.74 Delayed Quote.28.04%
SAUDI ARABIAN OIL COMPANY -0.14% 35.85 End-of-day quote.1.70%
VERICEL CORPORATION -1.25% 24.57 Delayed Quote.42.99%
WTI 1.79% 45.665 Delayed Quote.-28.04%
All news about MEDIWOUND LTD.
11/12MEDIWOUND : Presentation - November 2020
PU
11/10MediWound Reports Third Quarter 2020 Financial Results
GL
11/02MediWound to Report Third Quarter 2020 Financial Results and Host a Conferenc..
GL
10/28MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
GL
10/21MOVES-Moelis adds tech banker to expand in Israel - memo
RE
10/14MediWound Studying the Effect of EscharEx on Biofilm Burden
GL
09/16MediWound Announces FDA Acceptance of Biologics License Application for NexoB..
GL
09/15MEDIWOUND : Presentation - September 2020
PU
09/03MediWound to Present at Upcoming Investor Conferences in September
GL
08/25MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid t..
GL
More news
Financials (USD)
Sales 2020 20,7 M - -
Net income 2020 -10,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -9,44x
Yield 2020 -
Capitalization 100 M 100 M -
Capi. / Sales 2020 4,84x
Capi. / Sales 2021 3,24x
Nbr of Employees -
Free-Float 57,2%
Chart MEDIWOUND LTD.
Duration : Period :
MediWound Ltd. Technical Analysis Chart | MDWD | IL0011316309 | MarketScreener
Technical analysis trends MEDIWOUND LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 6,50 $
Last Close Price 3,68 $
Spread / Highest target 90,2%
Spread / Average Target 76,6%
Spread / Lowest Target 49,5%
EPS Revisions
Managers
NameTitle
Sharon Malka Chief Executive Officer
Stephen T. Wills Executive Chairman
Boaz Gur-Lavie Chief Financial Officer
Lior Rosenberg Chief Medical Officer
Ety Klinger Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDIWOUND LTD.18.39%100
CSL LIMITED6.66%99 506
SAMSUNG BIOLOGICS CO.,LTD.85.91%47 405
BIOGEN INC.-16.66%38 055
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.169.86%31 226
ALEXION PHARMACEUTICALS, INC.12.95%26 863